Multiple Peaking Phenomena in Pharmacokinetic Disposition
- 1 June 2010
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 49 (6), 351-377
- https://doi.org/10.2165/11319320-000000000-00000
Abstract
Multiple peaking in the blood fluid concentration-time curve is a phenomenon occasionally encountered in pharmacokinetics. When it occurs, it can create difficulties in the determination and interpretation of pharmacokinetic parameters. Multiple peaking can occur as a consequence of a number of different mechanisms. These include, in addition to others, factors related to the formulation, be it the drug chemical entity itself or other formulation-related factors such as the excipients incorporated into the product design. Another contributing factor that can work in concert with the formulation is the physiological makeup of the gastrointestinal tract itself. This includes the pH and components of bile such as bile salts and phospholipids, the secretion of which is regulated by hormonal and dietary factors. In some cases, biochemical differences in the regional areas of the gastrointestinal tract, such as regiospecificity in bile concentrations and/or transport proteins, could contribute to windows for absorption that result in multiple peaking of xenobiotics. One of the most common sources of multiple peaking is contributed by biliary secretion followed by intestinal reabsorption of a drug, a process for which the term ‘enterohepatic recycling’ has been coined. This cause of multiple peaking is associated with special consideration in the calculation and interpretation of the drug clearance and volume of distribution. In this review, each of these various causes of multiple peaking is discussed, with incorporation of relevant examples for illustrative purposes.Keywords
This publication has 226 references indexed in Scilit:
- Variability of Intestinal Expression of P-Glycoprotein in Healthy Volunteers as Described by Absorption of Talinolol from Four Bioequivalent TabletsJournal of Pharmaceutical Sciences, 2003
- Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited modelJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Pharmacokinetic Drug Interactions with Oral ContraceptivesClinical Pharmacokinetics, 1990
- Enterohepatic Circulation of Opioid DrugsClinical Pharmacokinetics, 1989
- Mean residence time for drugs subject to enterohepatic cyclingJournal of Pharmacokinetics and Biopharmaceutics, 1989
- A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: A double-site model for drug absorptionJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Pharmacokinetics of Ranitidine in Patients With Renal FailureThe Journal of Clinical Pharmacology, 1986
- Clinical Pharmacokinetics of CimetidineClinical Pharmacokinetics, 1983
- Estimating the fraction reabsorbed in drugs undergoing enterohepatic circulationJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the ratJournal of Pharmacokinetics and Biopharmaceutics, 1978